secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2022-02-11T23:59:59+00:00
Accession:  0001493152-22-003881
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo reports Q2 FY2022 net loss $1.1M; starts Phase 2 trial for ANEB-001; appoints new CEO
--------------------------------------------------------------------------------

- Net loss $1.1M ($0.05/sh) vs $0.3M ($0.03/sh) in Q2 FY2021; operating expenses $1.1M.
- Cash and cash equivalents $18.0M as of Dec 31, 2021; cash burn $1.2M in Q2.
- Initiated Phase 2 proof-of-concept study for ANEB-001 for acute cannabinoid intoxication; topline results expected H1 2022.
- Simon Allen appointed CEO effective Feb 1, 2022; previously CBO at Ambrx.
- FDA pre-IND meeting provided guidance; U.S. patent issued for ANEB-001 (expires 2040).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222003881/0001493152-22-003881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222003881/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-003881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer